Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2807165 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL641826 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL337401 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL10593578 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL3844302 | 0.97 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL1127413 | 0.97 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| Hypochlorous Acid SCHEMBL3761791 | 0.92 | — | — | |
| Sulfuric Acid SCHEMBL1670999 | 0.86 | KDM4E (0.39) | — | |
| Hydrochloric Acid SCHEMBL4615568 | 0.84 | — | — | |
| SCHEMBL29449732 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5973194-A | Process for preparing dialkylphosphinate salts | CLARIANT GMBH (DE) | 1999-10-26 | — | — | US | claimed |
| EP-0764223-B1 | METHOD OF PRODUCING A WATER-ABSORBING FLAT ARTICLE AND USE THEREOF | STOCKHAUSEN CHEM FAB GMBH (DE) | 1998-08-19 | — | — | EP | claimed |
| US-4306045-A | Process for producing acrylamide polymers | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1981-12-15 | — | — | US | claimed |
| JP-11043374-A | — | — | None | — | — | JP | disclosed |
| EP-4704914-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATES COMPRISING PNU-159682 DERIVATIVES | Merck Sharp & Dohme LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4701667-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250221935-A1 | STABLE NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2025-07-10 | — | — | US | disclosed |
| US-12226529-B2 | Stable nanolipoprotein particles and related compositions methods and systems | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024226388-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATES COMPRISING PNU-159682 DERIVATIVES | MERCK SHARP & DOHME LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024226410-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| US-12017188-B2 | Dendrimer particles and related mixed matrix filtration membranes, compositions, methods, and systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-06-25 | — | — | US | disclosed |
| WO-1989008459-A1 | PERFLUOROCHEMICAL EMULSION WITH STABILIZED VESICLES | ALPHA THERAPEUTIC CORPORATION (US) | 1989-09-21 | — | — | WO | disclosed |
| US-4857493-A | Polymer latexes containing metal ions and complexes | FORD WARREN T (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0320594-A2 | Aqeous crosslinkable resin dispersions, method of their production and use thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0315185-A2 | Process for preparation of water absorptive composite | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0293762-A2 | Process for the preparation of a water-absorptive fibrous substrate | UNI-CHARM CORPORATION (JP) | 1988-12-07 | — | — | EP | disclosed |
| US-4785021-A | OPTICAL RESOLUTION | RESEARCH DEVELOPMENT CORP. OF JAPAN (JP) | 1988-11-15 | — | — | US | disclosed |
| EP-0280541-A2 | Process for producing highly water absorptive polymer | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1988-08-31 | — | — | EP | disclosed |
| US-4694044-A | Adsorbent | RESEARCH DEVELOPMENT CORP. OF JAPAN (JP) | 1987-09-15 | — | — | US | disclosed |
| EP-0154343-A2 | Adsorbent | Research Development Corporation of Japan (JP) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221935-A1 | STABLE NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | HDLBP, CETP, PLIN3 | NOS3 4460/4885NOS1 4680/4885NOS2 4641/4885 |
| US-12226529-B2 | Stable nanolipoprotein particles and related compositions methods and systems | HDLBP, CETP, PLIN3 | NOS3 4519/4885NOS1 4702/4885NOS2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.